Loading...

CPRX CATALYST PHARMACEUTICALS INC Company Mergers 8-K Filing

CTLY

CPRX

CATALYST PHARMACEUTICALS INC

(CPRX)

2023 8-K

Show Summary

Summary

Patent Settlement Update

Patent Litigation Settlement

Financial Statements

Financial Statements

Drug Submission Update

Earnings Announcement

Director Departure

Corporate Presentation

Patent Settlement

Earnings Announcement

License Agreement with Kye ...

Annual Meeting Results

Earnings Reports

Earnings Reports

Publication of Study on Vam...

Public Offering

Corporate Presentation

Public Offering

Collaboration Partner NDA S...

CFO Retirement and Appointment

Earnings Reports

Patent Allowance

FDA Approval for AGAMREE

Appointment of CEO

FDA Acceptance of Supplemen...

Participation in Cantor Glo...

Earnings Reports

Retirement of CEO

Asset Acquisitions

License and Collaboration A...

Appointment of New Director

Earnings Report

FDA Meeting for FIRDAPSE Do...

Departure of Directors

Earnings Reports

Completion of Acquisition o...

Notice Letter from Teva Pha...

External Links:

CATALYST PHARMACEUTICALS, INC. has acquired an exclusive license to vamorolone, a potential treatment for Duchenne Muscular Dystrophy, for North America from Santhera Pharmaceuticals Holdings AG. With a $75 million all-cash purchase payment, the exclusive commercial rights extend to U.S., Canada, and Mexico. Catalyst Pharmaceuticals, INC. also has future rights for any approved indications of vamorolone and obtained a 11.26% stake in Santhera with a $15 million equity investment.

AI Assistant

CATALYST PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.